Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Pediatrics/Neonatology | Neurology
Clinical Trials: Neuroblastoma
A listing of clinical trials currently looking for volunteers to enroll in Neuroblastoma studies. Click on the closest city to find more detailed information on a research study in your area.
California
Duarte : City of Hope
COG ANBL00B1: Neuroblastoma Biology Studies
View More »
Los Angeles : Children's Hospital of Los Angeles
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
San Diego : Rady Children's Hospital
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
San Diego : Rady Children's Hospital
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Connecticut
Hartford : Connecticut Children's Hospital
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Hartford : Connecticut Children's Hospital
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Hartford : Connecticut Children's Hospital
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Florida
Orlando : Arnold Palmer Hospital for Children- MD Anderson
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Orlando : Arnold Palmer Hospital for Children- MD Anderson
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Orlando : Arnold Palmer Hospital for Children- MD Anderson
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Orlando : Arnold Palmer Hospital for Children- MD Anderson
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Georgia
Savannah : Memorial University Medical Center
ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
View More »
Atlanta : Children's Healthcare of Atlanta Childern Hosp - ATL
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Maryland
Baltimore : Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Massachusetts
Boston : Dana Farber Cancer Institute DFCI (3)
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Boston : Dana-Farber Cancer Institute
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Michigan
Ann Arbor : The University of Michigan Comprehensive Cancer Center
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
Grand Rapids : Helen DeVos Children's Hospital
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Grand Rapids : Helen DeVos Children's Hospital
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Grand Rapids : Helen DeVos Children's Hospital
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Grand Rapids : Helen DeVos Children's Hospital
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Minnesota
Missouri
Kansas : Children's Mercy Hospital (Kansas)
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Kansas City : Children's Mercy Hospitals and Clinics
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Kansas City : Children's Mercy Hospitals and Clinics
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Kansas City : Children's Mercy Hospitals and Clinics
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
St. Louis : Cardinal Glennon Children's Medical Center
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
New York
Bronx : Children's Hospital at Montefiore
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer
New York : Memorial Sloan Kettering Cancer Center
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
New York : Memorial Sloan-Kettering Cancer Center
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
North Carolina
Charlotte : Levine Children's Hospital
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
Charlotte : Levine Children's Hospital
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Charlotte : Levine Children's Hospital
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Charlotte : Levine Children's Hospital
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Ohio
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
131I-Metaiodobenzylguanidine (MIBG) with Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
131I-MIBG Expanded Access: An Open Label, Expanded Access Protocol Using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma
Cincinnati : Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder In Patients with Recurrent or Resistant Neuroblastoma IND# 68,254
View More »
Cincinnati : Cincinnati Children's Hospital Medical Center
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Pennsylvania
Pittsburgh : Children's Hospital of Pittsburgh
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
South Carolina
Charleston : Medical University of South Carolina
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Texas
Fort Worth : Cook Children's Medical Center
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Houston : Texas Children's Hospital
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Houston : Texas Children's Cancer and Hematology Centers
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Washington
Seattle : Seattle Children's Hospital CPKC412A2114
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Seattle : Seattle Children's
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Argentina
Buenos Aires : Prof. Dr. J. P. Garrahan National Children's Hospital
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Australia
Parkville : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Canada
Toronto : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
France
Lyon Cedex : Centre Léon Berard
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Paris : Institut Curie, Département de Pédiatrie
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Paris : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Villejuif : Institut Gustave Roussy, Département de Pédiatrie
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Villejuif Cedex : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Germany
Frankfurt : Hospital for Children and Adolescents II/III
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Freiburg : Klinik IV Pädiatrische Hämatologie, Onkologie Zentrum für Kinderheilkunde, Jugendmedizin UNIVERSITAT
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Hannover : Medizinische Hochschule Hannover
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Tübingen : Universitatslclinik fur Kininder-und Jugendmedizin
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Italy
Bologna : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Genova : Gaslini Children's Hospital, Paediatric Haematology-Oncology Department
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Milano : Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Milano : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Padova : Clinica di Oncoematologia Pediatrica, Dipartimento di Pediatria
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
View More »
Roma : Ospedale Pediatrico Bambin Gesù, Dipartimento di Oncoematologia Pediatrica
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
United Kingdom
Birmingham : Birmingham Children's Hospital NHS foundation
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Glasgow : Royal Hospital for Sick Children
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
London : Great Ormond Street Hospital for Children NHS Trust
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Newcastle Upon Tyne : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Sutton : Royal Marsden Hospital, Haemato-Oncology Unit, Institute of Cancer Research
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
View More »
Sutton : Novartis Investigative Site
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB